Posters

Intravitreal bevacizumab in the treatment of macular edema induced by retinal vein occlusions

Poster Details

First Author: V.Dimovska MACEDONIA

Co Author(s):                     

Abstract Details

Purpose:

Purpose: The aim of the study was to evaluate anatomical and morphological outcome following intravitreal bevacizumab (Avastin) in eyes with macular oedema secondary to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

Setting:

Twenty-two eyes (22 patients) with macular edema secondary to central retinal vein occlusion (10 eyes-45%) and branch retinal vein occlusion (12 eyes - 55%) were enrolled in prospective study conducted at the University Eye Clinic in Skopje.

Methods:

The patients were examined for best corrected visual acuity (BCVA), slit-lamp examination, tonometry, clinical examination on dilated pupil with 78/90 Dpt Volk lenses and Spectral Domain Optical Coherence Tomography (SD-OCT Topcon 3D 2000). Eyes were treated with three initial intravitreal bevacizumab injections of 1,25 mg/0,05 ml at a monthly interval. Re-treatment criteria were based on central retinal thickness (CRT) evaluated on optical coherence tomography and change in BCVA.

Results:

Mean age in the total group was 61,55 years; mean visual acuity gain obtained following treatment was 0,13 on Snellen’s chart. Average injections number was 4,91, with more injections applied in the group with CRVO. Average CRT difference following treatment was assessed on 265,18μm, with greater CRT decrease in the group of CRVO. Mean follow up was 1,4 years. No serious or sight threatening adverse effects were registered.

Conclusions:

Bevacizumab has proven as safe, effective and beneficial anti-VEGF drug for macular edema secondary to retinal vein occlusions, applied as primary therapy in treatment-naïve patients. Our experience suggests that more injections are associated with greater resolution of macular edema, evaluated by central retinal thickness values obtained by optical coherence tomography. The author has no financial interest to declare.

Financial Disclosure:

None